CA-MULTEFIRE-ALLIANCE
22.6.2021 14:02:13 CEST | Business Wire | Press release
MFA (MulteFire® Alliance), an international organization dedicated to enabling industry verticals to deploy private cellular networks globally, today announced its expanded mission to enable 5G private networks in unlicensed, shared and locally licensed spectrum by providing guidance to enterprises seeking to deploy their own network.
Leveraging existing 3GPP 5G specifications, MFA will deliver Uni5G Technology Blueprints to industry verticals. These blueprints will help enterprises select and implement the key features from the 3GPP standards that are relevant to their specific deployment. MFA will also develop best practices and deployment guides, including industry resources on understanding all available spectrum options for 5G private networks. The first Uni5G Technology Blueprint will be available in Q4 2021.
According to a recent industry report by ABI Research , the total addressable market size for 5G and 4G/LTE private network equipment for Industry 4.0 use cases will reach ~$35B by 2030.
“MFA paved the way for industries to contemplate how they can deploy their own private network in unlicensed spectrum using MulteFire 4G/LTE-based cellular technology with high-performance, built-in security and mobility benefits,” said Mazen Chmaytelli, president, MFA. “Now through our expanded role in enabling 5G private networks, MFA will provide industry verticals with practical guidance on deployment that will meet their unique requirements and determine which spectrum option is right for their site.”
MFA provides a unique global PLMN ID for 5G and MulteFire private networks to industry verticals
MFA has been awarded a global Public Land Mobile Network (PLMN) ID by the ITU. MFA is planning to make this PLMN ID available to industry verticals. The PLMN ID is a series of numbers that identifies a specific network and ensures that only authorized devices connect to that network.
With access to a unique global PLMN ID number, industry verticals are able to deploy their own 5G private network in locally licensed spectrum or a MulteFire private network in unlicensed spectrum today.
MFA members and others under MFA authorization are able to bundle the PLMN ID with their network equipment, thus simplifying the deployment process for enterprises by eliminating the need for them to separately apply for a PLMN ID.
“Across all industry verticals, we’re witnessing a drive to increase control, reliability and security through deployment of private networks,” said Chmaytelli. “Enterprises can now leverage locally licensed spectrum using Uni5G technology, and later can use global unlicensed or shared spectrum when 5G NR-U solutions become available. Through our Uni5G Technology Blueprints and our unique global PLMN ID, MFA has simplified the path to 5G private networks and is helping to accelerate the ecosystem.”
To join the MFA, learn more about Uni5G or how to access PLMN ID numbers, or receive notifications on the Uni5G Technology Blueprint, visit www.mfa-tech.org .
Resources:
- White Paper: “5G Private Networks for Maritime Use: Opportunities for Digital Port Automation,” Beecham Research
- White Paper: “The Importance of Spectrum Liberalization for Private 5G Networks,” ABI Research
- Video: Uni5G and MulteFire Private Networks for Manufacturing
About the MFA
MFA (MulteFire Alliance) is an international organization that is championing the global industry adoption of private cellular networks using MFA-defined MulteFire specifications for LTE and Uni5G technology blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005377/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
